Salm Sandra, Rutz Jochen, van den Akker Marjan, Blaheta Roman A, Bachmeier Beatrice E
Institute of Pharmaceutical Biology, Goethe University, Frankfurt, Germany.
Institute of General Practice, Goethe University, Frankfurt, Germany.
Front Pharmacol. 2023 Sep 28;14:1234701. doi: 10.3389/fphar.2023.1234701. eCollection 2023.
Herbal medicines are becoming increasingly popular among patients because they are well tolerated and do not exert severe side effects. Nevertheless, they receive little consideration in therapeutic settings. The present article reviews the current state of research on the clinical benefits of herbal medicines on five indication groups, psychosomatic disorders, gynecological complaints, gastrointestinal disorders, urinary and upper respiratory tract infections. The study search was based on the database PubMed and concentrated on herbal medicines legally approved in Europe. After applying defined inclusion and exclusion criteria, 141 articles were selected: 59 for psychosomatic disorders (100% randomized controlled trials; RCTs), 20 for gynecological complaints (56% RCTs), 19 for gastrointestinal disorders (68% RCTs), 16 for urinary tract infections (UTI, 63% RCTs) and 24 for upper respiratory tract infections (URTI) (79% RCTs). For the majority of the studies, therapeutic benefits were evaluated by patient reported outcome measures (PROs). For psychosomatic disorders, gynecological complaints and URTI more than 80% of the study outcomes were positive, whereas the clinical benefit of herbal medicines for the treatment of UTI and gastrointestinal disorders was lower with 55%. The critical appraisal of the articles shows that there is a lack of high-quality studies and, with regard to gastrointestinal disorders, the clinical benefits of herbal medicines as a stand-alone form of therapy are unclear. According to the current state of knowledge, scientific evidence has still to be improved to allow integration of herbal medicines into guidelines and standard treatment regimens for the indications reviewed here. In addition to clinical data, real world data and outcome measures can add significant value to pave the way for herbal medicines into future therapeutic applications.
草药在患者中越来越受欢迎,因为它们耐受性良好,不会产生严重的副作用。然而,在治疗环境中它们很少受到关注。本文综述了草药对五个适应症组(身心障碍、妇科疾病、胃肠道疾病、泌尿系统和上呼吸道感染)临床益处的研究现状。该研究检索基于PubMed数据库,并集中于欧洲合法批准的草药。在应用明确的纳入和排除标准后,选择了141篇文章:59篇关于身心障碍(100%随机对照试验;RCT),20篇关于妇科疾病(56%RCT),19篇关于胃肠道疾病(68%RCT),16篇关于尿路感染(UTI,63%RCT),24篇关于上呼吸道感染(URTI)(79%RCT)。对于大多数研究,治疗益处通过患者报告结局指标(PRO)进行评估。对于身心障碍、妇科疾病和URTI,超过80%的研究结果是阳性的,而草药治疗UTI和胃肠道疾病的临床益处较低,为55%。对这些文章的批判性评价表明,缺乏高质量的研究,并且就胃肠道疾病而言,草药作为一种独立治疗形式的临床益处尚不清楚。根据目前的知识状态,仍需改进科学证据,以便将草药纳入此处所综述适应症的指南和标准治疗方案。除了临床数据外,真实世界数据和结局指标可为草药进入未来治疗应用铺平道路增添重要价值。